# Platelet dense granule defect: experience in the French population

**Authors:** Delphine Borgel, Agathe Beauvais, Cécile Bally, Manal Ibrahim-Kosta, Annabelle Dupont, Camille Paris, Caroline Vayne, Sophie Voisin, Valérie Goin, Guillaume Nam-Nguyen, Rémi Favier, Arnaud Dupuis, Sebastien Eymieux, Jean-Claude Bordet, Emmanuelle Blanchard, Claire Auditeau, Dominique Lasne, Annie Harroche, Marie-Christine Alessi, Mathieu Fiore

PMC · DOI: 10.1016/j.rpth.2026.103364 · 2026-01-29

## TL;DR

This study examines how often a platelet disorder called DGD occurs in France and highlights the need for better diagnostic standards.

## Contribution

The study provides prevalence estimates of DGD in a French cohort and emphasizes the impact of diagnostic criteria on diagnosis rates.

## Key findings

- DGD prevalence ranged from 7.5% to 37.4% depending on diagnostic criteria.
- Standardized guidelines and repeated testing are essential for accurate DGD diagnosis.
- No significant differences in age, sex, or bleeding history were found between DGD and non-DGD patients.

## Abstract

Platelet dense granule defect (DGD) is a frequent inherited disorder that is underdiagnosed due to its complexity and poor standardization of diagnostic tools.

To assess the prevalence of DGD in a large real-life French cohort of patients with an abnormal bleeding score.

Patients with abnormal International Society on Thrombosis and Haemostasis Bleeding Assessment Tool scores, but no deficiency of coagulation or von Willebrand factor, and platelet counts > 100 × 109/L, were recruited between December 2019 and March 2023 across 8 French expert centers. At the first visit, platelet function testing included light transmission aggregometry, whole-mount transmission electron microscopy, the mepacrine assay, and evaluation of CD63 expression. Patients with suspected DGD, based on prior testing, were included directly at the confirmatory visit (V2). DGD was defined by abnormal results on whole-mount transmission electron microscopy, mepacrine assay, or CD63 assay, and was considered confirmed if abnormalities were reproducible across both visits.

Of the 119 patients included at the inclusion visit, 66 had at least 1 abnormal dense granule test, including 19 with ≤2. Among the 54 patients seen at confirmatory visit , 40 had confirmed abnormalities, including 8 with at least 2 abnormal tests. Depending on diagnostic criteria, DGD prevalence ranged from 7.5% (≥2 abnormalities) to 37.4% (≥1 abnormality). Among 46 patients included at confirmatory visit, 30 had a confirmed DGD, including 11 with at least 2 abnormalities. No significant differences in age, sex, International Society on Thrombosis and Haemostasis Bleeding Assessment Tool scores, or bleeding history were observed between patients with or without DGD.

DGD diagnosis in clinical practice depends on the criteria used. Standardized guidelines and repeated testing are essential for improving diagnostic accuracy.

•DGD is a frequent hereditary disease that is challenging to diagnose.•Prevalence of DGD was evaluated in the French population.•Prevalence of DGD ranged from 7.5% to 37.4% according to the diagnostic criteria used. ▪ Standardized guidelines and repeated testing are essential for improving diagnosis

DGD is a frequent hereditary disease that is challenging to diagnose.

Prevalence of DGD was evaluated in the French population.

Prevalence of DGD ranged from 7.5% to 37.4% according to the diagnostic criteria used. ▪ Standardized guidelines and repeated testing are essential for improving diagnosis

## Linked entities

- **Proteins:** CD63 (CD63 molecule)
- **Diseases:** von Willebrand disease (MONDO:0019565)

## Full-text entities

- **Genes:** F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, F7 (coagulation factor VII) [NCBI Gene 2155] {aka SPCA}, PTPN11 (protein tyrosine phosphatase non-receptor type 11) [NCBI Gene 5781] {aka BPTP3, CFC, JMML, METCDS, NS1, PTP-1D}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, F11 (coagulation factor XI) [NCBI Gene 2160] {aka FXI, PTA}, ITGA2B (integrin subunit alpha 2b) [NCBI Gene 3674] {aka BDPLT16, BDPLT2, CD41, CD41B, FMAIT2, GP2B}, ALG13 (ALG13 UDP-N-acetylglucosaminyltransferase subunit) [NCBI Gene 79868] {aka CDG1S, CXorf45, DEE36, EIEE36, GLT28D1, MDS031}, GP1BA (glycoprotein Ib platelet subunit alpha) [NCBI Gene 2811] {aka BDPLT1, BDPLT3, BSS, CD42B, CD42b-alpha, DBPLT3}, F8 (coagulation factor VIII) [NCBI Gene 2157] {aka AHF, DXS1253E, F8B, F8C, FVIII, HEMA}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, TRAP [NCBI Gene 100187907], WDTC1 (WD and tetratricopeptide repeats 1) [NCBI Gene 23038] {aka ADP, DCAF9}
- **Diseases:** Bruton agammaglobulinemia (MESH:C537409), bleeding tendency (MESH:C536965), epistaxis (MESH:D004844), Noonan syndrome (MESH:D009634), congenital disorder of glycosylation (MESH:D018981), Bleeding (MESH:D006470), platelet storage diseases (MESH:D010981), hereditary disease (MESH:D030342), Glanzmann thrombasthenia (MESH:D013915), hematological malignancies (MESH:D019337), Bernard-Soulier disease (MESH:D001606), oral cavity bleeding (MESH:D006472), Haemostasis (MESH:D020141), cardiofacial-cutaneous syndrome (MESH:C535349), inherited disorders of platelet function (MESH:D001791), defect (MESH:D000013), Thrombosis (MESH:D013927), VWF deficiencies (MESH:C531844), vascular injury (MESH:D057772), menorrhagia (MESH:D008595), coagulation factor (MESH:D020147), Platelet dense granule (DG) defect (MESH:C531691), deficiency of coagulation (MESH:D001778), DG anomaly (MESH:D015432)
- **Chemicals:** nucleotide (MESH:D009711), arachidonic acid (MESH:D016718), ATP (MESH:D000255), citrate (MESH:D019343), serotonin (MESH:D012701), calcium (MESH:D002118), sodium citrate (MESH:D000077559), ristocetin (MESH:D012310), DG (-), adenosine diphosphate (MESH:D000244), epinephrine (MESH:D004837), Mepacrine (MESH:D011796), EDTA (MESH:D004492)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966660/full.md

---
Source: https://tomesphere.com/paper/PMC12966660